Forest Laboratories FRX and Almirall announced today that Tudorza Pressair (aclidinium bromide inhalation
powder) 400mcg is now available in pharmacies throughout the United
States. Tudorza is a long-acting anticholinergic recently approved by
the U.S. Food and Drug Administration (FDA) for the long-term,
maintenance treatment of bronchospasm associated with chronic
obstructive pulmonary disease (COPD), including chronic bronchitis and
emphysema.
Tudorza is the first long-acting inhaled anticholinergic approved by the
FDA in over 8 years for COPD and is administered twice daily through the
preloaded, multidose Pressair inhaler.
Almirall granted commercialization rights in the U.S. for aclidinium to
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in